BioSpace News Archive

This Next-Generation DBS Technology Allows Physicians to Review Patient-Specific Brain Signals, Enabling More Personalized, Data-Driven Neurostimulation Treatment for Patients

eFFECTOR Therapeutics, Inc. and Pfizer Inc. announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E, a key oncogenic driver located downstream from both the RAS and PI3K signaling pathways.

Todos Medical Ltd. announced that it has entered into an exclusive option agreement to acquire Provista Diagnostics, Inc., an in vitro diagnostics company with a CLIA/CAP certified lab in Alpharetta, Georgia, developing and commercializing the proprietary Videssa® blood test for breast cancer.

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the initiation of a research collaboration with Janssen’s World Without Disease Accelerator*, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, announced today that the company’s chief executive officer, Paul Hastings, will present at the 38th Annual J.P. Morgan Healthcare Conference

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on its TACTI-002 and AIPAC studies for its lead product candidate, eftilagimod alpha (“efti” or “IMP321”).

Sebacia, Inc., a privately held commercial stage dermatology and aesthetics company, today provided a business update, first announcing an update to its leadership team.

Presage Biosciences, a biotechnology company pioneering a new cancer drug development approach using its CIVO® intratumoral microdosing platform, announced today that the U.S. Food and Drug Administration (FDA) has approved its first Exploratory Investigational New Drug (IND) application for a Phase 0 study utilizing its CIVO platform.

Omnicom Public Relations Group (OPRG), a division of Omnicom Group (NYSE: OMC) announced today a strategic alliance with LaVoieHealthScience (LHS) to bring global clients a broader set of integrated health- and science-experienced teams.

HealthCare Royalty Partners (“HCR” or the “Firm”), a global healthcare investment firm with $5.5 billion of cumulative capital commitments, today announced the closing on $1.83 billion for HealthCare Royalty Partners IV, L.P. (“Fund IV”) and affiliated entities.